drugset / Trial / NCT00110929

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

NCT00110929

Phase 2 Completed 850 enrolled Amgen
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to study the efficacy and safety of AMG 073 in patients with kidney failure who are being treated with hemodialysis or peritoneal dialysis and who also have secondary hyperparathyroidism (HPT).

Timeline

Start
2002-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cinacalcet Other / unclassified Oral